Pharvaris reported that deucrictibant, its oral bradykinin B2 receptor antagonist, met primary and secondary endpoints in a Phase III on‑demand study for hereditary angioedema (HAE). Topline results show rapid onset of symptom relief and a faster median time to response versus placebo; the company said it plans regulatory filings in the first half of 2026. The readout places Pharvaris in direct competition with KalVista’s Ekterly and other recent entrants, with analysts flagging rapid relief and complete symptom-resolution metrics as potential differentiators. HAE is a genetic disorder of episodic swelling driven by bradykinin pathways; on‑demand oral agents aim to replace injectable options for acute attacks.